The final trading day of the week promises to be full of action with regards to quarterly results, with over 50 companies ...

Laurus Labs' Q3 net profit soars to ₹252 crore with a 26% revenue increase, driven by strong generics and CDMO demand.

Laurus Labs Ltd. reported a 174% year-on-year increase in consolidated net profit to ₹252 crore for the third quarter of FY26, while revenue from operations grew 26% to ₹1,778 crore. The company's ...

Revenues for the quarter rose 26 percent to Rs.1,778 crore, supported by broad‑based strength across the generics and CDMO businesses.

Laurus Labs Q3 FY26: Revenue Up 30% YoY, Margins Expand to 26.1% 📈 | MCap 54,914.21 Cr - 9M FY26 revenue: ₹5,001 Cr, up 30% ...

Laurus Labs reported a significant 174% surge in net profit to ₹252 crore in Q3, driven by robust generic business and high demand in CDMO small molecule offerings.

Laurus Labs posted a manifold increase in net profit to ₹252 crore in the third quarter ended December 31, 2025, compared to ₹92 crore in the corresponding quarter of the previous financial year on ...

Laurus Labs Ltd (BOM:540222) reports robust financial results with significant growth in its generic division and strategic investments in advanced therapies.

In its investor presentation, Laurus Labs said that they are well on track to deliver healthy operational growth for financial year 2026.

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a ...